NM_030662.4:c.525C>T
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BA1
This summary comes from the ClinGen Evidence Repository: The filtering allele frequency of the c.525C>T (p.Ile175=) variant in the MAP2K2 gene is 0.255% (11/2418) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581) LINK:https://erepo.genome.network/evrepo/ui/classification/CA137952/MONDO:0021060/004
Frequency
Consequence
NM_030662.4 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MAP2K2 | NM_030662.4 | c.525C>T | p.Ile175Ile | synonymous_variant | Exon 4 of 11 | ENST00000262948.10 | NP_109587.1 | |
MAP2K2 | XM_047439100.1 | c.-46C>T | 5_prime_UTR_premature_start_codon_gain_variant | Exon 2 of 9 | XP_047295056.1 | |||
MAP2K2 | XM_006722799.3 | c.525C>T | p.Ile175Ile | synonymous_variant | Exon 4 of 9 | XP_006722862.1 | ||
MAP2K2 | XM_047439100.1 | c.-46C>T | 5_prime_UTR_variant | Exon 2 of 9 | XP_047295056.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000263 AC: 40AN: 152226Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000260 AC: 59AN: 226846Hom.: 0 AF XY: 0.000220 AC XY: 27AN XY: 122648
GnomAD4 exome AF: 0.000111 AC: 161AN: 1447014Hom.: 0 Cov.: 31 AF XY: 0.000109 AC XY: 78AN XY: 718554
GnomAD4 genome AF: 0.000263 AC: 40AN: 152226Hom.: 0 Cov.: 33 AF XY: 0.000336 AC XY: 25AN XY: 74370
ClinVar
Submissions by phenotype
not specified Benign:4
- -
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
- -
Variant summary: MAP2K2 c.525C>T alters a non-conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00025 in 252824 control chromosomes. The observed variant frequency is approximately 98.092 fold of the estimated maximal expected allele frequency for a pathogenic variant in MAP2K2 causing Noonan Syndrome and Related Conditions phenotype (2.5e-06), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.525C>T in individuals affected with Noonan Syndrome and Related Conditions and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as benign. -
RASopathy Benign:2
The filtering allele frequency of the c.525C>T (p.Ile175=) variant in the MAP2K2 gene is 0.255% (11/2418) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581) -
- -
Cardiovascular phenotype Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Noonan syndrome and Noonan-related syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at